CYP17A1 and prostate carcinoma: It is through inhibition of CYP17A1 that abiraterone exerts its prostate cancer treatment effect, yet ketoconazole is thought to be less selective, less potent, and has never been shown to demonstrate the same survival benefits as abiraterone.24